Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INT230-6 Monotherapy and Combination in Advanced Refractory Cancers
NCT03058289Phase 2Completed
- Sponsor
- Intensity Therapeutics
- Start
- Feb 2017
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of INT230-6 in breast cancer, head and neck cancer (HNC), squamous cell carcinoma (SCC), lymphoma, pancreatic cancer (PC), sponsored by Intensity Therapeutics. Started Feb 2017; status: completed.
02
Drugs
INT230-6
03
Conditions
breast cancerhead and neck cancer (HNC)squamous cell carcinoma (SCC)lymphomapancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03058289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03058289.